RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance

Core Insights - RxSight, Inc. reported record highs in Light Delivery Device (LDD) sales and Light Adjustable Lens (LAL) procedures during Q4 2024, significantly exceeding initial revenue guidance for the year [3][4] - The company serves approximately 15% of cataract surgeons in North America, with LAL procedures representing over 10% of the premium intraocular lens (IOL) market in the region [3] - RxSight plans to expand into international markets in Asia and Europe while continuing to innovate its RxSight system [3] Preliminary Financial Results - Preliminary unaudited revenue for Q4 2024 is expected to be around $40.2 million, reflecting a 41% increase year-over-year, driven by the sale of 29,069 LALs, a 61% increase in procedure volume compared to Q4 2023, and 83 LDDs sold, bringing the total installed base to 971 [7] - For the full year 2024, preliminary revenue is projected at approximately$ 139.9 million, a 57% increase from the previous year, supported by the sale of 98,055 LALs, a 79% increase in procedure volume, and 305 LDDs sold [7] 2025 Guidance - The company anticipates full-year 2025 revenue between $185.0 million and$ 197.0 million, indicating growth of approximately 32% to 41% over 2024 [4] - Expected gross profit margin for 2025 is projected to be in the range of 71% to 73% [4] - Operating expenses for 2025 are estimated to be between $165.0 million and$ 170.0 million, which includes non-cash stock-based compensation expenses of $22.0 million to$ 25.0 million [4]